Owing to the prolongation of OS in patients with many types of cancer, however, medical care expenditures, 7 especially oncology drug prices, are rapidly increasing not only in Japan but also worldwide. [8] [9] [10] [11] As an extreme case, the price of nivolumab (Opdivo® Ono Pharmaceutical Co., Ltd., Osaka, Japan), which is currently indicated for melanoma, non-small-cell lung cancer (NSCLC), bladder cancer, head and neck cancer, and Hodgkin's disease, has been set at ¥730 000 per 100 g, with the cost of treatment per patient estimated at ¥35 million per year. A Japanese government panel decided to cut the official price of nivolumab by 50% on the basis of social criticism in November 2016 that the drug was too expensive. 12 The primary objective of our analysis was to investigate whether OS and PFS are affected by oncology drug prices. In addition, prices
were compared between novel drugs and next-in-class drugs in terms of clinical benefits.
| ME THODS

| Data collection
All oncology drugs, including cytotoxic drugs as well as targeting agents and ICI, that were approved by the Japan Pharmaceuticals OS and PFS was obtained from the summary reports of approval for each drug in the PMDA homepage, 13 and actual OS and PFS data were obtained from the published original phase III pivotal studies, except for a comparative phase II study for trabectedin. The latest National Health Insurance Drug Price Standards were used to assess drug prices approved in Japan. 14 
| Data analysis
Relationship between drug prices and clinical outcomes were analyzed in two ways. First, the cost of a full course or 1 year of treatment was estimated on the basis of the latest National Health Insurance Drug Price Standards. 14 The relationship between cost and improvement in OS or PFS was then analyzed for each drug. We also compared the median price per year between drugs with novel mechanisms of action and next-in-class drugs (Table S1 ). The results were compared with findings previously reported in the USA. 15 Next, the drug costs were compared between experimental and control regimens in pivotal phase III studies. The costs required to prolong OS, PFS, or both, by 1 day, which was defined as the "cost index (CI)", were calculated as follows ( Figure 1 ). TA
| RE SULTS
We studied 45 drugs approved for 70 indications: 17 were approved on the basis of PFS, and 28 were approved on the basis of OS (Table 1) ; 17 had novel mechanisms, and 28 were next-in-class (Table S1) Figure 3 ).
The costs of antibody drugs required to prolong survival for 1 day tended to be the highest. 16 According to the criteria for calculating drug prices, drugs with a new mechanism of action, drugs that are safer and more effective than similar drugs, and drugs for rare diseases can be priced higher. 16 However, how to decide the prices of new drugs, or how to evaluate "cost-effectiveness" of new drugs, especially expensive oncology drugs, has not been disclosed in Japan.
| D ISCUSS I ON
Since the launch of the ICI nivolumab on the Japanese market, the extremely high price of this drug created a debate on the cost-effectiveness of oncology drugs among patients, oncologists, and the media in Japan. Cost-effectiveness is now one of the most serious problems related to oncology societies worldwide. In conclusion, the prices of oncology drugs should be decided on the basis of actual benefits to cancer patients, and the drug price evaluation process should be disclosed in Japan.
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